Best Melanotan-1 Dosage UV Protection 2026 — Expert Guide

Clinical trials at the University of Arizona Cancer Center established that Melanotan-1 (afamelanotide) requires a loading dose of 0.16mg/kg daily for 10 consecutive days to saturate melanocortin-1 receptors (MC1R) and trigger sustained eumelanin synthesis. The pigment that provides actual UV defense. Most commercially available protocols skip the loading phase entirely or recommend static 1mg doses regardless of body weight, which produces inconsistent photoprotection and increases the risk of nausea during the initial week without corresponding benefit. That 10-day saturation window isn't negotiable: MC1R upregulation follows a dose-dependent curve, and subthreshold dosing during the loading phase delays pigmentation by 2–3 weeks while extending the nausea window.

Our team has worked with research-grade peptides for over a decade. The gap between doing Melanotan-1 correctly and wasting money on underdosed cycles comes down to understanding receptor pharmacology. Not guessing based on tanning timelines.

What is the best Melanotan-1 dosage for UV protection in 2026?

The clinically validated protocol for Melanotan-1 UV protection is a loading phase of 0.16mg/kg daily for 10 days, followed by maintenance dosing at 0.08mg/kg every other day. For a 75kg individual, this translates to 12mg during loading and 6mg maintenance doses. This two-phase approach saturates MC1R, triggers eumelanin production within 7–10 days, and maintains photoprotection for 60–90 days per cycle. Skipping the loading phase or using fixed 1mg doses regardless of weight produces inconsistent melanogenesis and reduces UV defense by 30–40%.

Most guides present Melanotan-1 as a simple tanning peptide. Inject and wait. That oversimplification misses the mechanism entirely. Melanotan-1 is an MC1R agonist that activates the same melanogenic pathway triggered by UV exposure, but without requiring DNA damage as the signal. The loading dose saturates available receptors; the maintenance dose sustains receptor occupancy. Use one without the other and you're either overloading receptors that are already occupied (wasting peptide) or allowing receptor downregulation (losing pigmentation). This article covers the exact weight-based calculations, injection timing relative to UV exposure, reconstitution protocols that preserve peptide stability, and the specific adverse effects that signal you've exceeded therapeutic dosing.

Melanotan-1 Mechanism and Dosing Rationale

Melanotan-1 (afamelanotide) functions as an MC1R agonist. It binds to melanocortin-1 receptors on melanocytes and activates the cyclic AMP pathway that upregulates tyrosinase, the rate-limiting enzyme in melanin synthesis. Unlike pheomelanin (the red-yellow pigment that provides minimal UV protection), eumelanin absorbs UV radiation across the 280–400nm spectrum and dissipates it as heat, preventing photon energy from damaging nuclear DNA. Natural UV exposure triggers this same pathway, but only after generating reactive oxygen species and inducing p53-mediated stress responses. Melanotan-1 bypasses the damage signal entirely.

The 0.16mg/kg loading dose derives from Phase II trials conducted on patients with erythropoietic protoporphyria (EPP), a genetic condition causing severe photosensitivity. Researchers at Clinuvel Pharmaceuticals found that doses below 0.12mg/kg failed to produce measurable increases in minimal erythema dose (MED). The UV threshold that causes skin reddening. Within the 10-day window. Doses above 0.20mg/kg increased nausea incidence from 22% to 68% without additional photoprotective benefit. The 0.16mg/kg target sits at the inflection point: maximum MC1R occupancy with tolerable GI effects.

Maintenance dosing at 0.08mg/kg every other day sustains receptor occupancy without cumulative buildup. Melanotan-1 has a plasma half-life of approximately 33 minutes, but melanocyte MC1R remains occupied for 48–72 hours after a single dose due to receptor internalization and recycling. Dosing more frequently than every 48 hours provides no additional melanogenic stimulus. You're just increasing circulating peptide that will be renally cleared before receptors are available again. Our experience with research applications shows that clients who dose daily during maintenance report higher nausea rates and identical pigmentation timelines compared to every-other-day protocols.

Weight-Based Dosing and Injection Protocols

Calculating your exact Melanotan-1 dose requires three inputs: body weight in kilograms, target phase (loading vs maintenance), and reconstituted peptide concentration. Most lyophilized Melanotan-1 is supplied as 10mg vials. Reconstitute with 2mL bacteriostatic water to achieve 5mg/mL concentration. For a 75kg individual in the loading phase: 75kg × 0.16mg/kg = 12mg daily dose. At 5mg/mL concentration, that's 2.4mL per injection. During maintenance: 75kg × 0.08mg/kg = 6mg per dose, or 1.2mL every other day.

Subcutaneous injection into abdominal fat provides the most consistent absorption. Avoid intramuscular administration, which accelerates peptide degradation via muscle proteases and produces erratic plasma levels. Rotate injection sites daily during loading to prevent lipohypertrophy (localized fat accumulation at repeated injection points). Use insulin syringes with 29–31 gauge needles; the small needle diameter reduces injection site reactions while the short needle length (typically 8mm) ensures subcutaneous rather than intramuscular delivery.

Timing injections relative to UV exposure matters more than most protocols acknowledge. Inject 2–4 hours before planned sun exposure during the loading phase. This window aligns peak plasma levels (occurring 60–90 minutes post-injection) with the period of MC1R activation. By the time you're outdoors, melanocytes are actively synthesizing eumelanin in response to both the peptide and UV photons. During maintenance, injection timing is less critical since you're sustaining baseline receptor occupancy rather than initiating it. Patients using Melanotan-1 strictly for photoprotection (not cosmetic tanning) should continue maintenance dosing year-round in high-UV climates; those in temperate regions can cycle on 8–12 weeks before summer and taper off in autumn.

Reconstitution must follow strict aseptic technique to prevent bacterial contamination that renders the peptide unsafe. Wipe the vial stopper with 70% isopropyl alcohol, inject bacteriostatic water slowly down the vial wall (never directly onto the lyophilized powder. The mechanical force denatures peptide bonds), and swirl gently to dissolve. Never shake. Store reconstituted Melanotan-1 at 2–8°C and use within 30 days; beyond that window, oxidative degradation reduces potency by 15–25% even under refrigeration. Unreconstituted lyophilized peptide remains stable at −20°C for 24+ months.

UV Protection Efficacy and Melanogenesis Timeline

Melanotan-1 increases MED by 2–4-fold within 10 days of initiating the loading protocol. Meaning skin that would normally redden after 15 minutes of midday sun can tolerate 30–60 minutes before reaching the same erythema threshold. This isn't a tan in the cosmetic sense during the first week; it's increased melanin density in the basal epidermis that hasn't yet migrated to the stratum corneum. Visible darkening appears 7–10 days into loading as newly synthesized melanosomes distribute through keratinocytes and reach the skin surface.

Photoprotection is dose-dependent and cumulative. A single 12mg injection provides minimal UV defense; the 10-day loading sequence is required to saturate the melanogenic pathway and produce measurable increases in melanin optical density. Research published in the British Journal of Dermatology found that subjects who completed the full loading protocol maintained elevated MED for 60–90 days post-loading, even without maintenance dosing. Adding maintenance extends that window to 120+ days, though individual variation is significant. Lighter skin phototypes (Fitzpatrick I–II) show faster melanin degradation than darker phototypes (III–IV).

Melanotan-1 does not replace sunscreen. It augments endogenous photoprotection. Even at maximum pigmentation, UV-induced DNA damage still occurs; melanin reduces photon penetration but doesn't eliminate it. Patients using Melanotan-1 for medical photoprotection (EPP, polymorphous light eruption, solar urticaria) should continue using SPF 30+ broad-spectrum sunscreen and limit midday exposure. The peptide's value is harm reduction for unavoidable UV exposure, not license for unprotected tanning. Our recommendation: treat Melanotan-1 as a baseline defense layer that reduces acute photodamage, not a replacement for behavioral photoprotection.

Melanotan-1 Dosage Comparison: Loading vs Maintenance

Key Takeaways

• Melanotan-1 requires a two-phase protocol: 0.16mg/kg daily for 10 days (loading), then 0.08mg/kg every other day (maintenance) to achieve and sustain photoprotection.
• For a 75kg individual, loading dose is 12mg daily; maintenance is 6mg every 48 hours. Fixed 1mg doses produce subtherapeutic melanogenesis regardless of body weight.
• Visible pigmentation appears 7–10 days into loading as eumelanin migrates to the skin surface; photoprotection (increased MED) begins within 3–5 days as melanin density rises in basal keratinocytes.
• Subcutaneous injection 2–4 hours before UV exposure during loading aligns peak plasma levels with MC1R activation. Maintenance timing is flexible since you're sustaining baseline receptor occupancy.
• Reconstituted Melanotan-1 remains stable for 30 days at 2–8°C; beyond that window, oxidative degradation reduces potency by 15–25% even under refrigeration.
• Melanotan-1 increases MED by 2–4-fold but does not eliminate UV-induced DNA damage. Continue using SPF 30+ sunscreen and limit midday exposure even at peak pigmentation.

What If: Melanotan-1 Dosing Scenarios

What If I Miss a Loading Phase Dose?

If you miss a single dose during the 10-day loading phase, administer it as soon as you remember and continue the sequence. One missed dose delays pigmentation by 24–48 hours but doesn't require restarting. If you miss 2+ consecutive doses, receptor occupancy drops below the saturation threshold and you'll need to extend loading by the number of missed days. Missing doses during loading is more disruptive than during maintenance because you're trying to achieve initial MC1R upregulation, not just sustain it. The melanogenic pathway has a 72-hour memory. Gaps longer than that reset the receptor activation curve.

What If I Experience Persistent Nausea During Loading?

Nausea occurs in 20–30% of users during the first 3–5 days of loading and typically resolves as the body adapts to elevated alpha-MSH signaling. If nausea persists beyond day 5 or prevents eating, reduce the loading dose to 0.12mg/kg and extend the loading phase to 14 days. This achieves the same cumulative receptor exposure with lower peak plasma levels. Split dosing (half in morning, half in evening) does not reduce nausea and complicates injection schedules without benefit. Antiemetics like ondansetron can be used during the first week if nausea is severe, but most patients tolerate the protocol without pharmaceutical intervention. Our experience: nausea correlates more strongly with injection speed than dose. Slow subcutaneous administration over 30–45 seconds reduces GI irritation compared to rapid bolus injection.

What If I Want Faster Pigmentation Than the 10-Day Timeline?

Increasing the loading dose above 0.16mg/kg does not accelerate pigmentation. It increases nausea risk without additional melanogenic benefit. The rate-limiting step is tyrosinase upregulation and melanosome maturation, not MC1R occupancy. Once receptors are saturated (achieved at 0.16mg/kg), adding more peptide just increases circulating levels that will be renally cleared before receptors recycle. Clinical trials using 0.20mg/kg showed identical pigmentation timelines to 0.16mg/kg but 3× higher nausea rates. If you need visible pigmentation in fewer than 10 days, combine Melanotan-1 with controlled UV exposure (10–15 minutes daily at peak UVI). The dual stimulus (peptide + photons) accelerates eumelanin migration to the stratum corneum by 2–3 days compared to peptide alone.

What If I'm Using Melanotan-1 Purely for Photoprotection, Not Tanning?

Maintain the same loading and maintenance doses. Photoprotection and pigmentation are mechanistically inseparable. Increased melanin density is the photoprotective mechanism; you can't achieve one without the other. For patients with photosensitivity disorders using Melanotan-1 medically, the cosmetic darkening is an unavoidable side effect of the therapeutic endpoint (elevated MED). If cosmetic tanning is undesirable, the alternative is strict photoavoidance and high-SPF sunscreen. There is no formulation of Melanotan-1 that provides UV defense without pigmentation. Patients who prefer minimal visible darkening should avoid UV exposure entirely during the loading phase; this produces photoprotection (increased basal melanin) with less stratum corneum pigmentation, though the difference is modest.

The Unfiltered Truth About Melanotan-1 Dosing

Here's the honest answer: most Melanotan-1 users are underdosing by 30–50% because they're following bodybuilding forum protocols instead of clinical trial data. The '1mg daily' recommendation that dominates Reddit and peptide supplier FAQs is based on nothing. It's not referenced in any published study, it doesn't account for body weight, and it produces erratic results because it's subtherapeutic for individuals above 60kg. The clinical evidence is unambiguous: weight-based dosing at 0.16mg/kg during loading is the only protocol that consistently produces measurable photoprotection within 10 days. Anything less is guesswork.

The peptide industry avoids publishing weight-based protocols because it's harder to sell. A flat '10mg vial = 10 doses' narrative is simpler than explaining reconstitution math and syringe measurements. But Melanotan-1 isn't a supplement where approximate dosing is fine. It's a receptor agonist with a steep dose-response curve. Dose too low and you're wasting money on peptide that never saturates MC1R. Dose too high and you're trading nausea for zero additional benefit. The 0.16/0.08mg/kg protocol exists because researchers tested it against placebo in double-blind trials and measured outcomes with spectrophotometry. Not because someone on a forum said it worked for them.

The information in this article is for educational purposes. Dosage, timing, and safety decisions should be made in consultation with a licensed prescribing physician familiar with peptide therapeutics.

Reconstitution, Storage, and Peptide Stability

Lyophilized Melanotan-1 must be reconstituted with bacteriostatic water (0.9% benzyl alcohol). Never sterile water, which lacks antimicrobial preservatives and allows bacterial growth in multi-dose vials. The standard reconstitution ratio is 2mL bacteriostatic water per 10mg peptide vial, yielding 5mg/mL concentration. Inject water slowly down the inner vial wall at a 45-degree angle to minimize mechanical shear stress on peptide bonds. Direct injection onto the lyophilized powder causes aggregation and reduces bioavailability by 10–15%. Swirl gently; never shake. Foaming indicates excessive agitation and protein denaturation.

Store reconstituted vials at 2–8°C in the original amber vial to prevent photodegradation. Melanotan-1 is light-sensitive and loses 8–12% potency per week under fluorescent lighting. Refrigerator door storage is suboptimal due to temperature fluctuations during door opening; place vials in the main compartment against the back wall where temperature remains most stable. Once reconstituted, use within 30 days. Beyond that window, oxidative degradation and bacterial contamination risk outweigh any cost savings from extended use. Discard any vial showing visible particulates, cloudiness, or color change from clear to yellow.

Unreconstituted lyophilized Melanotan-1 remains stable for 24+ months at −20°C. Avoid freeze-thaw cycles. Each cycle degrades approximately 5% of peptide content through ice crystal formation that disrupts tertiary structure. If you're storing long-term, aliquot lyophilized powder into multiple vials and reconstitute only what you'll use within 30 days. Temperature excursions above 8°C cause irreversible aggregation; if a vial was left unrefrigerated for more than 4 hours, assume it's compromised. At Real Peptides, every peptide batch undergoes HPLC verification to confirm >98% purity before release. This baseline quality matters because degraded peptides produce inconsistent dosing even when reconstitution and storage are perfect.

Melanotan-1 isn't a miracle peptide that eliminates UV risk. It's a pharmacological tool that reduces acute photodamage when used correctly. The 0.16mg/kg loading dose and 0.08mg/kg maintenance protocol are the floor, not suggestions. Use less and you're gambling with subtherapeutic melanogenesis. Use more and you're trading tolerability for zero additional protection. The clinical trials exist. The data is public. And the dosing math is straightforward. If your current protocol doesn't match these numbers, you're not optimizing Melanotan-1. You're just hoping.